Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece.
Mol Biol Rep. 2012 Dec;39(12):10873-9. doi: 10.1007/s11033-012-1984-2. Epub 2012 Oct 12.
This case control study aims to investigate the role of HSP90 Gln488His (C > G), HSP70-2 P1/P2, HIF-1 alpha C1772T and HSPA8 intronic 1541-1542delGT polymorphisms as potential risk factors and/or prognostic markers for breast cancer. 113 consecutive incident cases of histologically confirmed ductal breast cancer and 124 healthy cases were recruited. The above mentioned polymorphisms were genotyped; multivariate logistic regression was performed. HSP90 GG (His/His) genotype was associated with elevated breast cancer risk. Similarly, the allele dose-response model pointed to increase in breast cancer risk per G allele. HSP70-2 P1/P2, HSPA8 intronic 1541-1542delGT and HIF-1 alpha polymorphisms were not associated with breast cancer risk, as evidenced by the dose-response allele models. The positive association between HSP90 G allele and breast cancer risk seemed to pertain to both premenopausal and postmenopausal women. With respect to survival analysis, none of the aforementioned polymorphisms was associated with either disease-free survival or overall survival. HSP90α Gln488His polymorphism seems to be a risk factor for breast cancer. On the other hand, our study did not point to excess risk conferred by HSPA8 1541-1542delGT, Hsp70-2 P1/P2 and HIF-1α C1772T.
本病例对照研究旨在探讨 HSP90 Gln488His (C > G)、HSP70-2 P1/P2、HIF-1α C1772T 和 HSPA8 内含子 1541-1542delGT 多态性作为乳腺癌潜在的风险因素和/或预后标志物的作用。招募了 113 例经组织学证实的导管乳腺癌新发病例和 124 例健康对照。对上述多态性进行了基因分型；进行了多变量逻辑回归分析。HSP90 GG（His/His）基因型与乳腺癌风险升高相关。同样，等位基因剂量反应模型表明，每个 G 等位基因都会增加乳腺癌风险。HSP70-2 P1/P2、HSPA8 内含子 1541-1542delGT 和 HIF-1α 多态性与乳腺癌风险无关，这可以从等位基因剂量反应模型中得到证明。HSP90 G 等位基因与乳腺癌风险之间的正相关似乎与绝经前和绝经后妇女均相关。就生存分析而言，上述多态性均与无病生存或总生存无关。HSP90α Gln488His 多态性似乎是乳腺癌的一个风险因素。另一方面，我们的研究并没有指出 HSPA8 1541-1542delGT、Hsp70-2 P1/P2 和 HIF-1α C1772T 会增加风险。
